Key result
A novel de novo KCNQ2 mutation [c.683A > G (p.His228Arg)] was identified as the presumable cause of severe, treatment-resistant infantile-onset neonatal seizures in a 3-month-old boy.
Case Report (n=1)
Identifies a novel KCNQ2 mutation (c.683A > G) associated with severe, treatment-resistant early-onset epileptic encephalopathy.
May inform genetic counseling in refractory neonatal seizures; extends KCNQ2 variant spectrum but remains hypothesis-generating.
Benetou C, Papailiou S, Maritsi D, Anagnostopoulou K, Kontos H, Vartzelis G. A novel de novo KCNQ2 mutation in a child with treatmentresistant early-onset epileptic encephalopathy. Turk J Pediatr 2019; 61: 279-281. Mutations in KCNQ2 gene, encoding for voltage-gated K+ channel subunit, may result in a wide spectrum of early-onset epileptic disorders. The phenotype of the disease varies from `benign familial neonatal seizures` to `severe epileptic encephalopathies`. In this report, we present a novel mutation [namely: c.683A > G (p.His228Arg)], as a presumable cause of severe infantile-onset neonatal seizures, in a 3-month old boy. The seizures have been poorly responsive to various pharmacological treatments, with phenytoin and carbamazepine presenting with the most favourable results so far. The study of our patient could help to further clarify the clinical manifestations of KCNQ2 mutations, revealing a previously unreported mutation.
No takes yet. Share an insight, caveat, or question.
Benetou et al. (2019) conducted a case report in Treatment-resistant early-onset epileptic encephalopathy (n=1). c.683A > G (p.His228Arg) KCNQ2 mutation was evaluated on Clinical manifestations and seizure response to treatment. A novel de novo KCNQ2 mutation [c.683A > G (p.His228Arg)] was identified as the presumable cause of severe, treatment-resistant infantile-onset neonatal seizures in a 3-month-old boy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: